Why was adalimumab important in the development of fully human monoclonal antibodies?

Created from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.

Diagram of an antibody molecule showing two identical light chains and two identical heavy chains joined by disulfide bonds in a Y-shaped structure, with labeled regions for antigen binding and effector function. — antibody The four-chain structure of an antibody, or immunoglobulin, molecule. The basic unit is composed of two identical light (L) chains and two identical heavy (H) chains, which are held together by disulfide bonds to form a flexible Y shape. Each chain is composed of a variable (V) region and a constant (C) region.

Adalimumab is significant in the history of biotechnology because it was the first fully human monoclonal antibody developed using phage display technology to receive approval for clinical use in humans.1

While early methods for creating monoclonal antibodies often relied on mouse cells or hybrid DNA techniques—which could trigger immune responses in patients—phage display allowed researchers to engineer human antibody proteins and express them on the surfaces of bacteriophage particles. This breakthrough enabled the production of antibodies that are entirely human in origin, reducing the likelihood of adverse reactions. Following its approval in 2002, adalimumab became a vital therapy for conditions such as rheumatoid arthritis, marking a major milestone in the development of targeted, human-derived medical treatments.1